KarXT

Bristol Myers partner Zai Lab plots KarXT filing in China after trial win
Fierce Pharma
Tue, 10/29/24 - 08:00 pm
Bristol Myers Squibb
Cobenfy
Zai Lab
KarXT
China
For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been
Fierce Pharma
Mon, 10/7/24 - 11:16 am
Bristol Myers Squibb
KarXT
Cobenfy
schizophrenia
FDA eyes first schizophrenia drug shift in decades
Axios
Thu, 09/26/24 - 11:02 am
Bristol Myers Squibb
FDA
KarXT
schizophrenia
3 FDA approval dates to watch in the year’s final push
Pharma Voice
Wed, 09/11/24 - 11:39 am
FDA
Bristol Myers Squibb
KarXT
schizophrenia
Regeneron
Sanofi
Dupixent
COPD
BridgeBio
acoramidis
ATTR cardiomyopathy
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
Pharma Voice
Mon, 08/19/24 - 09:58 am
Bristol Myers Squibb
KarXT
FDA
schizophrenia
AbbVie
5 FDA Decisions to Watch in the Second Half of 2024
BioSpace
Mon, 06/24/24 - 11:29 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Adaptimmune
afami-cel
advanced synovial sarcoma
Lykos Therapeutics
MDMA
PTSD
Bristol Myers Squibb
KarXT
schizophrenia
Daiichi Sankyo
AstraZeneca
Dato-DXd
non-small cell lung cancer
As BMS announces major cuts, its Karuna deal looks poised to drive growth
Pharma Voice
Tue, 04/30/24 - 08:29 am
Karuna Therapeutics
schizophrenia
Bristol Myers Squibb
clinical trials
KarXT
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
Reuters
Sun, 04/7/24 - 04:42 pm
Bristol Myers Squibb
schizophrenia
clinical trials
KarXT
Bristol Myers to acquire brain drug developer Karuna for $14B
BioPharma Dive
Fri, 12/22/23 - 09:44 am
Bristol Myers Squibb
Karuna Therapeutics
schizophrenia
M&A
KarXT
FDA kicks off review of Karuna’s schizophrenia drug KarXT
Pharmaphorum
Wed, 11/29/23 - 11:57 am
Karuna
KarXT
FDA
schizophrenia
Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug
Fierce Biotech
Fri, 11/17/23 - 11:31 am
Karuna Therapeutics
KarXT
blood pressure
schizophrenia
Karuna submits schizophrenia drug for US approval
BioPharma Dive
Thu, 09/28/23 - 12:02 pm
Karuna Therapeutics
KarXT
schizophrenia
FDA
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Endpoints
Thu, 03/23/23 - 11:49 am
Royalty Pharma
Karuna Therapeutics
KarXT
schizophrenia
PureTech
Karuna’s schizophrenia drug succeeds in a second late-stage trial
BioPharma Dive
Mon, 03/20/23 - 09:53 am
Karuna
clinical trials
schizophrenia
KarXT
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
Fierce Biotech
Tue, 01/10/23 - 06:37 pm
JPMHC 2023
Karuna Therapeutics
drug launches
schizophrenia
KarXT
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Fierce Biotech
Mon, 01/9/23 - 10:31 am
Karuna Therapeutics
schizophrenia
KarXT
drug launches
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
BioPharma Dive
Tue, 12/6/22 - 08:45 pm
Karuna Therapeutics
Pharma CEOs
schizophrenia
FDA
KarXT
Karuna’s resurrection of Lilly drug delivers phase 3 schizophrenia success, teeing up 2023 filing
Fierce Biotech
Mon, 08/8/22 - 10:14 am
Karuna Therapeutics
clinical trials
schizophrenia
KarXT

Pages